PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Vertex surprised by FDA hold on diabetes trial

Trials for Vertex Pharmaceuticals’ investigational stem cell-derived diabetes therapy have been halted by the U.S. FDA, taking the biotech by surprise.

The agency placed a clinical hold on the Phase 1/2 clinical trial of VX-880, saying there was not enough information to support giving patients the full dose of the drug. The biotech said it was “surprised by the clinical hold placed on the study” and that the patients dosed so far had reported positive reports. VX-880 is an investigational allogeneic stem cell-derived, fully differentiated, insulin-producing islet cell therapy manufactured using Vertex’s proprietary technology.

So far, there have been three patients dosed in the study. The first two received a half-dose of the treatment. The first patient was able to stop using insulin less than a year after dosing, with data indicating his body is now able to control its blood sugar levels. The second patient in the study is also responding well to the treatment and has been able to cut insulin use by one-third.

The third patient was given a full dose of the treatment after an independent monitoring committee gave the nod to up the dosage. This patient is only 29 days out from dosing and has experienced no adverse events so far.

No serious adverse events have been reported in response to treatment. Side effects experienced included headache and hypomagnesemia, which were unrelated to treatment, according to Vertex.

Wall Street investors have kept a close eye on VX-880, as the drug has the potential to reach blockbuster status, according to Bloomberg Intelligence. Type 1 diabetes is a genetic condition where the pancreas stops producing insulin. Left untreated, it can lead to serious problems in the kidneys, heart and eyes. The condition affects about 1.6 million Americans and there is currently no permanent cure.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026